Literature DB >> 33275556

Building a Canadian Translational Bladder Cancer Research Network.

Madhuri Koti1,2, David M Berman1,2,3, D Robert Siemens1,4, Dirk Lange5, Edwin Wang, Paul Toren6, Bernhard J Eigl5, Céline Hardy1,3, Robert Purves7, Vincent Fradet6, Yves Fradet6, Jose Mansure8, Wassim Kassouf8, Peter C Black5.   

Abstract

Entities:  

Year:  2020        PMID： 33275556      PMCID： PMC7716841          DOI： 10.5489/cuaj.6887

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  29 in total

1.  Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.

Authors:  Jason E Duex; Kalin E Swain; Garrett M Dancik; Richard D Paucek; Charles Owens; Mair E A Churchill; Dan Theodorescu
Journal:  Mol Cancer Res       Date:  2017-10-02       Impact factor: 5.852

2.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

Review 3.  Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.

Authors:  Gottfrid Sjödahl; Chelsea L Jackson; John Ms Bartlett; D Robert Siemens; David M Berman
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

4.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

5.  Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Authors:  Gillian Vandekerkhove; Tilman Todenhöfer; Matti Annala; Werner J Struss; Amanda Wong; Kevin Beja; Elie Ritch; Sonal Brahmbhatt; Stanislav V Volik; Jörg Hennenlotter; Matti Nykter; Kim N Chi; Scott North; Arnulf Stenzl; Colin C Collins; Bernhard J Eigl; Peter C Black; Alexander W Wyatt
Journal:  Clin Cancer Res       Date:  2017-07-31       Impact factor: 12.531

6.  Single-cell Sequencing Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of Human Bladder Cancer Stem Cells.

Authors:  Zhao Yang; Chong Li; Zusen Fan; Hongjie Liu; Xiaolong Zhang; Zhiming Cai; Liqin Xu; Jian Luo; Yi Huang; Luyun He; Chunxiao Liu; Song Wu
Journal:  Eur Urol       Date:  2016-07-04       Impact factor: 20.096

7.  Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Authors:  Manav Korpal; Xiaoling Puyang; Zhenhua Jeremy Wu; Roland Seiler; Craig Furman; Htoo Zarni Oo; Michael Seiler; Sean Irwin; Vanitha Subramanian; Jaya Julie Joshi; Chris K Wang; Victoria Rimkunas; Davide Tortora; Hua Yang; Namita Kumar; Galina Kuznetsov; Mark Matijevic; Jesse Chow; Pavan Kumar; Jian Zou; Jacob Feala; Laura Corson; Ryan Henry; Anand Selvaraj; Allison Davis; Kristjan Bloudoff; James Douglas; Bernhard Kiss; Morgan Roberts; Ladan Fazli; Peter C Black; Peter Fekkes; Peter G Smith; Markus Warmuth; Lihua Yu; Ming-Hong Hao; Nicholas Larsen; Mads Daugaard; Ping Zhu
Journal:  Nat Commun       Date:  2017-07-24       Impact factor: 14.919

8.  EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.

Authors:  Jonathan Rosenberg; Srikala S Sridhar; Jingsong Zhang; David Smith; Dean Ruether; Thomas W Flaig; Joaquina Baranda; Joshua Lang; Elizabeth R Plimack; Randeep Sangha; Elisabeth I Heath; Jamie Merchan; David I Quinn; Sandy Srinivas; Matthew Milowsky; Chunzhang Wu; Elaina M Gartner; Peiying Zuo; Amal Melhem-Bertrandt; Daniel P Petrylak
Journal:  J Clin Oncol       Date:  2020-02-07       Impact factor: 44.544

Review 9.  Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.

Authors:  Joaquim Bellmunt
Journal:  Biomedicines       Date:  2018-08-02

10.  The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Authors:  Véronique Ouellet; Armen Aprikian; Alain Bergeron; Fadi Brimo; Robert G Bristow; Simone Chevalier; Darrel Drachenberg; Ladan Fazli; Neil E Fleshner; Martin Gleave; Pierre Karakiewicz; Laurence Klotz; Louis Lacombe; Jean-Baptiste Lattouf; Theodorus van der Kwast; Jeremy A Squire; Mathieu Latour; Dominique Trudel; Anne-Marie Mes-Masson; Fred Saad
Journal:  BMC Urol       Date:  2018-09-10       Impact factor: 2.264
View more
  1 in total

1.  Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.

Authors:  Peter C Black; Nimira Alimohamed; Wassim Kassouf; John L Gore; Kathy D McCoy; Brad H Nelson; Daniel D De Carvalho; Rodney J Ouellette; Ferg Devins; Tony Cornacchia; D Robert Siemens; David M Berman; Srikala S Sridhar; Girish Kulkarni
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.